Applied StemCell and Syntax Bio collaborate to advance next-generation regenerative medicine
Applied StemCell (ASC) is excited to announce a strategic collaboration with Syntax Bio focused on advancing stem cell research and accelerating the development of future regenerative medicine applications.
The collaboration will evaluate our engineered iPSC and hypoimmunogenic cell platforms using Syntax Bio’s proprietary Cellgorithm™ platform, combining our expertise in genome engineering and cell engineering with Syntax Bio’s programmable cell technology.
Together, we aim to support the development of more reproducible, scalable approaches for cell therapy research, therapeutic application discovery, and future manufacturing workflows.
“By combining our cell engineering expertise with Syntax Bio’s Cellgorithm™ platform, we see an opportunity to help accelerate the development of more reproducible, scalable approaches for cell therapy research and manufacturing.”
– Dolores Baksh, Ph.D.
CEO of Applied StemCell
Key areas of collaboration
- Engineered iPSC platforms
- Hypoimmunogenic cell line development
- Genome engineering and cell engineering
- Stem cell research and regenerative medicine
- Cell therapy discovery and development
- Scalable manufacturing approaches
